ArticleBMC veterinary research2026
A novel tulathromycin oil suspension injection: preparation, characterization, and pharmacokinetics in goats.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Tulathromycin (TUL), a semisynthetic macrolide antibiotic, is effective against respiratory tract infections across diverse animal species and is widely used for their prevention and treatment in veterinary medicine. However, the clinical application of TUL is currently limited by the sole availability of an injectable formulation, which may restrict its broader clinical adoption. In the present study, an injection of a TUL oil suspension with 10% drug loading was prepared using the colloid mill dispersion method, and corresponding pharmacokinetic studies were conducted in goats. The resulting preparation was obtained as a milky white suspension whose sedimentation volume ratio, redispersibility, syringeability and injectability, and pH value conformed to the technical standards of the Ministry of Agriculture of the People’s Republic of China. In vitro release studies revealed that the TUL oil suspension exhibited a slower release rate compared with the commercially available injection. Furthermore, in vivo pharmacokinetic studies in goats demonstrated that it significantly delayed absorption (Tmax: 2.33 ± 0.52 h vs. 0.58 ± 0.13 h, P < 0.01) and increased AUC0−∞ by 50.44% (14382.53 ± 1654.23 h·ng/mL vs. 9567.98 ± 1166.02 h·ng/mL, P < 0.01), corresponding to a relative bioavailability of 150.44%. CL was reduced by 37.93% (P < 0.01), and T1/2 was prolonged by 12.64 h (83.32 h vs. 70.68 h). These results highlight the therapeutic potential of this novel formulation, which, with its demonstrated sustained-release profile and enhanced bioavailability, presents a commercially viable and therapeutically promising option against respiratory infections in goats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.